.Risk
predictors to primary endpoint - ICU admission, need for MV and hospital
mortality
Tocilizumab (2.6%), convalescent plasma (16.5%), oseltamivir (29.6%)
and others antibiotics (79.7%), excluding AZM, were administered as
adjunct therapy. Among patients admitted to the ICU, 57.6% (68)
received vasopressor and supplemental oxygen without positive pressure
was used in 56.9% (254). Positive non-invasive ventilation including
HFNC and BiPAP were used in 23.9% (107) while MV in 21.1% (97). HFNC
oxygen therapy was able to prevent the patient’s progression to MV in
31.8% of cases.
Overall, 86.7% (398) were discharged alive and 4.5% (21) were still
hospitalized by dataset freeze date. Of patients admitted to the ICU,
25.7% (35) died and when MV was required, the mortality increased to
34.0% (33). Among dead patients, the median age was 83.3 years (IQR,
75.5 to 89.5) with the length of stay in hospital of 25.3 (SD±22.5)
days, 22.8 (SD±18.7) in ICU and 21.2 (SD±17.3) in MV. The main clinical
predictors related to increase the risk for mortality
(>70%), were: age >65 years, presence of up
one comorbidity, pulmonary involvement ≥50%, saturation
<93%, lymphocyte <900mm3,
D-dimers >1,250 ng/mL and CRP >8.0 mg/dL at
admission, oxygen requirement through BiPAP or HFNC, and ICU admission
and MV required during hospitalization were also associated with a
higher risk of death (Figure 2) (Table).